Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.45 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23178175 | 0.89 | KDM4E (0.47) | MEN1ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL2016900 | 0.80 | LMNA (0.48) | GAAMEN1ALDH1A1MAPTHPGD | |
| Hydrochloric Acid SCHEMBL2018001 | 0.79 | LMNA (0.47) | GAAMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL3309908 | 0.76 | MEN1 (0.65) | MEN1ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL24330250 | 0.76 | EPHX2 (0.55) | MEN1KMT2AGNAI3GNAO1GNAI1 | |
| SCHEMBL11682924 | 0.75 | MTNR1A (0.50) | MEN1ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL256673 | 0.75 | — | — | |
| SCHEMBL3551415 | 0.75 | GNAI3 (0.72) | MEN1ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL5313764 | 0.74 | GAA (0.58) | GAAMEN1ALDH1A1KMT2ADPP4 | |
| Hydrochloric Acid SCHEMBL28162204 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263604-A1 | Oxidase inhibitors and their use | ORYZON GENOMICS, S.A. (ES) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263604-A1 | Oxidase inhibitors and their use | MAOA, PNPO, MAOB | GAA 382/4885MEN1 4506/4885ALDH1A1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.